• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Belgium·Healthcare·AGMB
Held by 1 Guru
Share

AgomAb Therapeutics NV Stocks

$ 14.5Last Updated 07.08.2026

Issuer Rating

1/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 714.10M

$ 14.5
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%

Latest news

06.02.2026 15:00

Agomab Therapeutics IPO: Pfizer and Sanofi-backed biotech starts trading

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of AGMB is 34.6 and suggests 139% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.08.2026 15:11

Intel expanded its stock offering and raised $20 billion

11.08.2026 15:06

A "Glass" iPhone Is Coming. Apple Will Radically Revamp Its Design in 2027 — Bloomberg

11.08.2026 12:38

AI-Driven Investing: Which Small-Cap Funds Outperformed the Russell 2000?

11.08.2026 12:03

Hong Kong's main technology index will be expanded by nearly double to include AI companies

11.08.2026 11:09

OpenAI bought back $7 billion worth of shares from employees at the old price. The price has not risen since March.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026